Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1997 1
1999 1
2001 1
2003 1
2004 1
2006 1
2012 1
2017 2
2018 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial.
Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, Ommen VV, Wildberger JE. Nijssen EC, et al. Among authors: vermeeren ma. Lancet. 2017 Apr 1;389(10076):1312-1322. doi: 10.1016/S0140-6736(17)30057-0. Epub 2017 Feb 21. Lancet. 2017. PMID: 28233565 Clinical Trial.
Contrast material-induced nephropathy in the era of hydration.
Nijssen EC, Vermeeren MA, Janssen MM, Kessels FA, van Ommen VV, Rennenberg RJ, Wildberger JE. Nijssen EC, et al. Among authors: vermeeren ma. Radiology. 2012 Dec;265(3):978-9; author reply 979. doi: 10.1148/radiol.12121162. Radiology. 2012. PMID: 23175552 No abstract available.
[Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial].
Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, van Ommen V, Wildberger JE. Nijssen EC, et al. Among authors: vermeeren ma. Ned Tijdschr Geneeskd. 2018;161:D1734. Ned Tijdschr Geneeskd. 2018. PMID: 29328007 Clinical Trial. Dutch.
12 results